Q BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride SR89 and Metastron, a radiopharmaceutical therapeutic for the treatment of metastatic bone cancer pain. It is also developing Man-01, a pre-clinical lead candidate for the treatment of primary open angle glaucoma; QBM-001 for rare pediatric non-verbal autism spectrum disorder; and Uttroside-B for liver cancer. Q BioMed Inc. has a partnership with Mannin Research Inc. for the development of therapeutics to treat acute respiratory distress syndrome, glaucoma, kidney diseases, and others. The company was formerly known as ISMO Tech Solutions, Inc. and changed its name to Q BioMed Inc. in July 2015. Q BioMed Inc. was incorporated in 2013 and is based in New York, New York.

CEO

Mr. Denis D. Corin

Employees

Country

United States

ISIN

US74736N1054

Listings

0 Comments

Share your thoughts

FAQ

What is Q BioMed stock price today?▼

The current price of QBIO is $0.00 USD — it has increased by +0% in the past 24 hours. Watch Q BioMed stock price performance more closely on the chart.

What is Q BioMed stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on OTCM exchange Q BioMed stocks are traded under the ticker QBIO.

What is Q BioMed revenue for the last year?▼

Q BioMed revenue for the last year amounts to 568,000 USD.

What is Q BioMed net income for the last year?▼

QBIO net income for the last year is -6.99M USD.

How many employees does Q BioMed have?▼

As of August 16, 2026, the company has 3 employees.

In which sector is Q BioMed located?▼

Q BioMed operates in the Health & Wellness sector.

When did Q BioMed complete a stock split?▼

The last stock split for Q BioMed was on August 07, 2015 with a ratio of 1.5:1.

Where is Q BioMed headquartered?▼

Q BioMed is headquartered in New York, United States.